Search

Your search keyword '"Kuo, Fang-Ying"' showing total 169 results
Start Over Author "Kuo, Fang-Ying" Publication Year Range Last 50 years
169 results on '"Kuo, Fang-Ying"'

14. Overall survival among patients who undergo resection does not differ significantly between T1a and T1b hepatocellular carcinoma based on the 8th American Joint Commission on Cancer.

Author

Liu, Yueh-Wei, Li, Wei-Feng, Kuo, Fang-Ying, Eng, Hock-Liew, Wang, Chih-Chi, Lin, Chih-Che, Yong, Chee-Chien, and Yen, Yi-Hao

Abstract

Purpose: The 8th edition of the American Joint Committee on Cancer (AJCC) staging system for hepatocellular carcinoma (HCC) has been used since 2018. However, whether any significant difference in overall survival (OS) exists between patients with T1a and T1b HCC who undergo resection has been controversial. We aim to clarify this issue. Methods: We consecutively enrolled newly diagnosed HCC patients who underwent liver resection (LR) from 2010 to 2020 at our institution. OS was estimated using the Kaplan–Meier method and compared using log-rank tests. Prognostic factors for OS were identified by multivariate analysis. Results: This study enrolled 1250 newly diagnosed HCC patients who underwent LR. No significant differences in OS were identified between patients with T1a and T1b tumors among all patients (p = 0.694), cirrhotic patients (p = 0.753), non-cirrhotic patients (p = 0.146), patients with alpha-fetoprotein (AFP) > 20 ng/ml (p = 0.562), patients with AFP ≤ 20 ng/ml (p = 0.967), patients with Edmondson grade 1 or 2 (p = 0.615), patients with Edmondson grade 3 or 4 (p = 0.825), patients positive for hepatitis B surface antigen (HBsAg; p = 0.308), in patients positive for anti-hepatitis C virus (HCV) antibody (p = 0.781), or patients negative for both HBsAg and anti-HCV antibody (p = 0.125). Using T1a as the reference, multivariate analysis showed that T1b is not a significant predictive factor for OS (hazard ratio (HR): 1.338; 95% confidence interval (CI):0.737–2.431; p = 0.339). Conclusion: No significant difference in OS was observed between patients who underwent LR to treat T1a and T1b HCC tumors. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

16. Characteristics and prognosis of patients with large well-differentiated hepatocellular carcinoma who have undergone resection

Author

Lin, Shu-Hsien, primary, Eng, Hock-Liew, additional, Liu, Yueh-Wei, additional, Lin, Chih-Che, additional, Yong, Chee-Chien, additional, Wang, Chih-Chi, additional, Chen, Chao-Long, additional, Kuo, Fang-Ying, additional, Cheng, Yu-Fan, additional, Wang, Jing-Houng, additional, Yen, Yi-Hao, additional, Liu, Ting-Ting, additional, Li, Wei-Feng, additional, and Chen, Chien-Hung, additional

Published
2022
Full Text
View/download PDF

22. Clinical and novel application of FibroScan, FIB‐4 and aspartate aminotransferase‐to‐platelet ratio index in liver fibrosis evaluation in patients with hepatocellular carcinoma and their roles in oesophageal variceal prediction

Author

Huang, Tzu‐Hsin, primary, Lin, Ming‐Tsung, additional, Wang, Jing‐Houng, additional, Chang, Kuo‐Chin, additional, Yen, Yi‐Hao, additional, Kuo, Fang‐Ying, additional, Huang, Chao‐Cheng, additional, Hsiao, Chang‐Chun, additional, Chiu, Sherry Yueh‐Hsia, additional, Lu, Sheng‐Nan, additional, Wang, Chih‐Chi, additional, and Hu, Tsung‐Hui, additional

Published
2021
Full Text
View/download PDF

39. The association between steatosis and diabetes with hepatocellular carcinoma in non-genotype 3 chronic hepatitis C patients

Author

Yen, Yi-Hao, primary, Lin, Ming-Tsung, additional, Kuo, Fang-Ying, additional, Chang, Kuo-Chin, additional, Tsai, Ming-Chao, additional, Tseng, Po-Lin, additional, Wu, Cheng-Kun, additional, Lin, Jung-Ting, additional, Hu, Tsung-Hui, additional, Lu, Sheng-Nan, additional, Wang, Jing-Houng, additional, Hung, Chao-Hung, additional, and Chen, Chien-Hung, additional

Published
2017
Full Text
View/download PDF

41. Living Donor Liver Transplantation for Combined Hepatocellular Carcinoma and Cholangiocarcinoma: Experience of a Single Center

Author

Chang, Cheng-Chih, primary, Chen, Ying-Ju, additional, Huang, Tzu-Hao, additional, Chen, Chun-Han, additional, Kuo, Fang-Ying, additional, Eng, Hock-Liew, additional, Yong, Chee-Chien, additional, Liu, Yueh-Wei, additional, Lin, Ting-Lung, additional, Li, Wei-Feng, additional, Lin, Yu-Hung, additional, Lin, Chih-Che, additional, Wang, Chih-Chi, additional, and Chen, Chao-Long, additional

Published
2017
Full Text
View/download PDF

43. The association between steatosis and diabetes with hepatocellular carcinoma in non‐genotype 3 chronic hepatitis C patients.

Author

Yen, Yi‐Hao, Lin, Ming‐Tsung, Kuo, Fang‐Ying, Chang, Kuo‐Chin, Tsai, Ming‐Chao, Tseng, Po‐Lin, Wu, Cheng‐Kun, Lin, Jung‐Ting, Hu, Tsung‐Hui, Lu, Sheng‐Nan, Wang, Jing‐Houng, Hung, Chao‐Hung, and Chen, Chien‐Hung

Subjects
DIABETES, LIVER cancer, CHRONIC hepatitis C, RIBAVIRIN, INTERFERONS
Abstract

Abstract: Background & Aims: Diabetes mellitus (DM) has been found to be strongly associated with an increased risk of hepatocellular carcinoma (HCC) among chronic hepatitis C (CHC) patients. Several studies have also found an association between metabolic steatosis and the risk of HCC in CHC patients, whether this latter association has been accounted for by the known relationship between DM and HCC is still unknown. Methods: A cohort consisting of 976 non‐genotype 3 patients histologically proven to have CHC and treated with interferon and ribavirin was studied. Cumulative incidence and HCC risk were analysed using the Kaplan‐Meier method and Cox proportional hazard analysis. Results: Hepatocellular carcinoma developed in 140 subjects over a median follow‐up period of 97.3 months, while 699 patients achieved sustained virological response (SVR). According to multivariate analyses, age ≥ 60 years, advanced fibrosis and genotype 1 were identified as independent factors significantly associated with HCC development in SVR patients. Furthermore, using the absence of steatosis and absence of DM as references, the presence of steatosis without DM (HR = 2.09, 95% CI = 1.12‐3.9, P = .021), the presence of DM without steatosis (HR = 2.78, 95% CI = 1.3‐5.92, P = .008) and the combined presence of steatosis and DM (HR = 3.25, 95% CI = 1.44‐7.33, P = .004) were identified as independent factors significantly associated with HCC development in the SVR patients. In contrast, steatosis alone, DM alone and the combined presence of steatosis and DM were not associated with HCC development in non‐SVR patients. Conclusions: Steatosis and DM may be associated with HCC development in non‐genotype 3 CHC patients with SVR. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

49. Incidence of needle tract seeding and responses of soft tissue metastasis by hepatocellular carcinoma postradiotherapy

Author

Tung, Wei‐Chih, primary, Huang, Yu‐Jie, additional, Leung, Stephen Wan, additional, Kuo, Fang‐Ying, additional, Tung, Hung‐Da, additional, Wang, Jing‐Houng, additional, Hung, Chao‐Hung, additional, Lee, Chuan‐Mo, additional, Changchien, Chi‐Sin, additional, Yeh, Shih‐An, additional, Sun, Li‐Min, additional, Huang, Eng‐Yen, additional, Hsu, Hsuan‐Chih, additional, Wang, Chong‐Jong, additional, and Lu, Sheng‐Nan, additional

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results